Drici M D, Coccoz F, Morand P, Lapalus P
Laboratoire de pharamacologie expérimentale et clinique, Faculté de médecine, Nice.
Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:161-5.
Calcium is involved in several biochemical atherogenesis processes and its activity is antagonised in cell and animal experimental models by all classes of slow channel calcium inhibitors. However, the doses required in animals to slow the development of atherosclerotic lesions are above therapeutically acceptable doses in man. The clinical relevance of their anti-atherosclerotic activity in the few clinical studies undertaken is difficult to assess because of the variable criteria of judgment used.
钙参与了多个生物化学动脉粥样硬化形成过程，在细胞和动物实验模型中，各类慢通道钙抑制剂均可拮抗其活性。然而，在动物模型中减缓动脉粥样硬化病变发展所需的剂量高于人体治疗可接受剂量。由于所采用的判断标准各异，在已开展的少数临床研究中，这些药物抗动脉粥样硬化活性的临床相关性难以评估。
